In Work Package 2, we are working on the development, testing, and production of new light-activated treatments specifically designed for use in CHI. Under the supervision of Dennis Löwik, Wiert Kolkman is synthesizing special light-sensitive compounds in the lab that are combined with a targeting molecule called Exendin at Radboud University.
These light-sensitive compounds can absorb light and produce reactive substances that can neutralize cells. By combining them with Exendin — which naturally binds to a specific receptor on beta cells—we aim to develop a treatment that can seek out and eliminate only the overactive beta cells involved in CHI, without harming healthy tissue.
The Exendin molecules are provided by our partners Fritz Andreae and Andreas Artl from the company PiChem, who are also supporting the production process for future clinical use.
Quick links to other Work Packages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9